A novel intronic mutation, 2988G>A, with high predictivity for impaired dunction of cytochrome P450 2D6 in white subjects

[1]  M. Eichelbaum,et al.  CYP2D6 genotyping strategy based on gene copy number determination by TaqMan real‐rime PCR , 2003, Human mutation.

[2]  M. Kennedy,et al.  Correlation of CYP2D6 genotype with perhexiline phenotypic metabolizer status. , 2003, Pharmacogenetics.

[3]  Andrea Gaedigk,et al.  CYP2D6 poor metabolizer status can be ruled out by a single genotyping assay for the -1584G promoter polymorphism. , 2003, Clinical chemistry.

[4]  W. Koch,et al.  Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. , 2003, Clinical chemistry.

[5]  A. Daly,et al.  Pharmacogenetics of the major polymorphic metabolizing enzymes , 2003, Fundamental & clinical pharmacology.

[6]  A. Rettie,et al.  Expression, Purification, Biochemical Characterization, and Comparative Function of Human Cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 Allelic Isoforms , 2002, Journal of Pharmacology and Experimental Therapeutics.

[7]  T. Eschenhagen,et al.  Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment. , 2002, Pharmacogenetics.

[8]  G. Tucker,et al.  In-vitro analysis of the contribution of CYP2D6.35 to ultra-rapid metabolism. , 2001, Pharmacogenetics.

[9]  M Schwab,et al.  Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. , 2001, Pharmacogenetics.

[10]  A. Molven,et al.  Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism? , 2001, Pharmacogenetics.

[11]  U. Meyer.  Pharmacogenetics and adverse drug reactions , 2000, The Lancet.

[12]  M Schwab,et al.  Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. , 2000, Pharmacogenetics.

[13]  J. Idle,et al.  Medical implications of HGP's sequence of chromosome 22 , 2000, The Lancet.

[14]  M. Ingelman-Sundberg,et al.  Duplication, multiduplication, and amplification of genes encoding drug-metabolizing enzymes: evolutionary, toxicological, and clinical pharmacological aspects. , 1999, Drug metabolism reviews.

[15]  L. Bertilsson,et al.  10‐hydroxylation of nortriptyline in white persons with 0, 1, 2, 3, and 13 functional CYP2D6 genes , 1998, Clinical pharmacology and therapeutics.

[16]  M. Eichelbaum,et al.  Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. , 1998, Pharmacogenetics.

[17]  J. Lafitte,et al.  Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. , 1997, Pharmacogenetics.

[18]  J. Brockmöller,et al.  Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. , 1997, American journal of human genetics.

[19]  A. Molven,et al.  Homologous unequal cross-over involving a 2.8 kb direct repeat as a mechanism for the generation of allelic variants of human cytochrome P450 CYP2D6 gene. , 1995, Human molecular genetics.

[20]  D. Schrenk,et al.  The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. , 1994, Pharmacogenetics.

[21]  M. Ingelman-Sundberg,et al.  Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[22]  U. Meyer,et al.  Evolution of a highly polymorphic human cytochrome P450 gene cluster: CYP2D6. , 1992, Genomics.

[23]  R. Skoda,et al.  The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. , 1989, American journal of human genetics.

[24]  M. Eichelbaum,et al.  A sensitive capillary GC assay for the determination of sparteine oxidation products in microsomal fractions of human liver. , 1986, Life sciences.

[25]  Ulrich M. Zanger,et al.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry , 2003, Naunyn-Schmiedeberg's Archives of Pharmacology.